<DOC>
	<DOCNO>NCT00235820</DOCNO>
	<brief_summary>Placebo-Controlled Study Comparing Safety Efficacy Adalimumab Methotrexate Placebo Subjects Moderate Severe Chronic Plaque Psoriasis</brief_summary>
	<brief_title>Safety Efficacy Adalimumab Methotrexate Placebo Subjects With Moderate Severe Chronic Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Subject age 18 old good health ( Investigator discretion ) recent stable medical history diagnosis psoriasis least 12 month stable moderate severe chronic plaque psoriasis Subject candidate systemic therapy phototherapy active psoriasis despite treatment topical agent . Subject able willing selfadminister sc injection available qualified person ( ) administer sc injection . Male subject must hve vasectomized practice birth control . Previous systemic antiTNF therapy . Prior use MTX . Known hypersensitivity constituent adalimumab . Systemic therapy psoriasis least 4 week prior Baseline ; except biologic therapy , must discontinue least 12 week prior enrollment . Topical psoriasis therapy least 2 week prior Baseline , except noncorticosteroid shampoo , bland ( alpha beta hydroxy ) emollients low potency topical corticosteroid palm , sol , face , inframammary area , groin . Use tan bed , excessive sun exposure , phototherapy ( UVB , UVA ) , least 2 week prior Baseline . Use PUVA least 4 week prior Baseline . Use oral injectable corticosteroid study . Subject consider investigator , reason , unsuitable candidate study . Female subject pregnant breast feeding consider become pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>adalimumab</keyword>
</DOC>